NEW YORK (GenomeWeb News) – Correlogic Systems this week said that it has fulfilled European Union regulatory requirements to CE Mark its OvaCheck test for epithelial ovarian cancer. The test is a multiplex assay that measures the relative ratios of eight proteins. The Germantwon, Md.-based firm said that it is currently in discussions with potential partners for distribution of OvaCheck in Europe.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.